Palvella Therapeutics (NASDAQ:PVLA) Upgraded by Stephens to “Strong-Buy” Rating

Stephens upgraded shares of Palvella Therapeutics (NASDAQ:PVLA) to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports.

A number of other brokerages have also issued reports on PVLA. Truist Financial set a $210.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Mizuho boosted their target price on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. BTIG Research boosted their target price on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Buy” and an average target price of $199.53.

Palvella Therapeutics Stock Up 3.0%

NASDAQ:PVLA opened at $125.79 on Tuesday. Palvella Therapeutics has a 12 month low of $20.20 and a 12 month high of $151.18. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of -30.17 and a beta of -0.13. The company’s 50 day moving average is $125.41 and its 200-day moving average is $103.44.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). Research analysts predict that Palvella Therapeutics will post -5.28 EPS for the current fiscal year.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, Director Elaine J. Heron purchased 2,400 shares of the stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $125.00 per share, with a total value of $300,000.00. Following the acquisition, the director directly owned 47,812 shares of the company’s stock, valued at $5,976,500. This represents a 5.28% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director George M. Jenkins purchased 4,000 shares of the stock in a transaction on Friday, February 27th. The stock was acquired at an average cost of $125.00 per share, for a total transaction of $500,000.00. Following the acquisition, the director directly owned 187,171 shares in the company, valued at approximately $23,396,375. This trade represents a 2.18% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. WCM Investment Management LLC acquired a new stake in shares of Palvella Therapeutics in the 1st quarter valued at $4,982,000. KBC Group NV acquired a new stake in shares of Palvella Therapeutics in the 1st quarter valued at $28,000. Swiss National Bank boosted its stake in shares of Palvella Therapeutics by 36.6% in the 1st quarter. Swiss National Bank now owns 19,400 shares of the company’s stock valued at $2,418,000 after purchasing an additional 5,200 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Palvella Therapeutics by 65.3% in the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock valued at $79,852,000 after purchasing an additional 253,128 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Palvella Therapeutics by 10.9% in the 1st quarter. Bank of New York Mellon Corp now owns 18,041 shares of the company’s stock valued at $2,249,000 after purchasing an additional 1,777 shares in the last quarter. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.